We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Urology

Journal Scan / Research · September 25, 2019

Results of a Study of an LHRH Agonist ± Abiraterone Acetate + Prednisone for High-Risk Prostate Cancer

European Urology


Additional Info

Disclosure statements are available on the authors' profiles:

European Urology
Clinical and Biological Characterisation of Localised High-Risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-Releasing Hormone Agonist With or Without Abiraterone Acetate Plus Prednisone
Eur Urol 2019 Oct 01;76(4)418-424, E Efstathiou, JW Davis, L Pisters, W Li, S Wen, RP McMullin, M Gormley, D Ricci, M Titus, A Hoang, AJ Zurita, N Tran, W Peng, T Kheoh, A Molina, P Troncoso, CJ Logothetis

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.

Further Reading